Clinical trials in lupus: What have we learned so far?

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1025-1027

  Bruce, Ian N ^a,b   Gordon, Caroline ^c   Merrill, Joan T ^d   Isenberg, David ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; BELIMUMAB; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; EPRATUZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB;

CLINICAL ASSESSMENT TOOL; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; OPEN STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TIME FACTORS;

EID: 77953502551     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep462     Document Type: Editorial

References (14)

1. Lu TY, Ng KP, Cambridge G et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
2. Wallace DJ, Stohl W, Furie RA et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61: 1168-78.
3. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
4. Merrill JT, Neuwelt CM, Wallace DJ et al. Rituximab in extra-renal SLE patients showed no significant difference compared to placebo at 52 weeks in the randomised, double-blind Phase II/III Study: EXPLORER. Ann Rheum Dis 2009;68(Suppl. 3):249.
5. Merrill JT, Burgos-Vargas R, Westhovens R et al. Activity of abatacept in SLE: results of a 12-month phase II exploratory study. Ann Rheum Dis 2009;68(Suppl. 3):70.
6. Furie RA, Looney RJ, Rovin E et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III lunar study. Arthritis Rheum 2009;60(Suppl. 1): S429.
7. Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial. Nat Rev Drug Discov 2009;8:688.
8. Boumpas DT, Austin HA, 3rd, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
9. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
10. Yee CS, Farewell V, Isenberg DA et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300-5.
11. Merrill JT, Mhatre M, Carthen F et al. Mycophenolate mofetil (MMF) is effective for systemic lupus (SLE) arthritis, final results of an organ-specific, double-blind, placebocontrolled trial. Arthritis Rheum 2009;60(Suppl. 1):S97.
12. Furie RA, Petri MA, Wallace DJ et al. Novel evidencebased systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
13. Reuters. UCB and immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE) 2009. http://www.reuters.com/article/pressRelease/idUS59586±27-Aug-2009±GNW20090827 (26 November 2009, date last accessed).
14. Petri M, Furie R, Merrill J et al. Four-year experience of belimumab, a BLyS-specific inhibitor, in systemic lupus erythematosus (SLE) patients. Arthritis Rheum 2009; 60(Suppl. 1):S774.